I just listened to the call and actually found the things they said regard Hep-C quite useful. If they are giving us up-to-date info then neither Vertex nor Schering are customers as they are both (far along) in Phase 3. They also mentioned no significant Hep-C revenue till 2011.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.